Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline: a randomized controlled trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2010 Jun;115(6):1141-1149.

doi: 10.1097/AOG.0b013e3181e0119c.

Affiliations

Randomized Controlled Trial

Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline: a randomized controlled trial

Bliss Kaneshiro et al. Obstet Gynecol. 2010 Jun.

Abstract

Objective: To estimate whether doxycycline, a matrix metalloproteinase inhibitor, would decrease unscheduled bleeding associated with initiation of a continuous oral contraceptive pill.

Methods: Participants initiating a continuous oral contraceptive pill (20 micrograms of ethinyl estradiol/90 micrograms of levonorgestrel) were randomly assigned to receive either doxycycline (100 mg orally twice daily) or placebo taken for 5 days at the onset of each bleeding or spotting episode during the first 84 days of the study period. For the final 28 days of the study, participants were observed on the oral contraceptive pill alone. The primary outcome was the number of bleeding and spotting days. A sample size of 66 (33 in each arm) was calculated to detect a 50% reduction in bleeding (beta=0.80, alpha=0.05) and accounted for a 30% dropout rate.

Results: Sixty-six women were randomly assinged (33 in each study group). There were no significant differences during the 84-day treatment in bleeding or spotting days (doxycycline [mean {standard error}, placebo, P=.32) or the length of the longest bleeding or spotting episode (doxycycline, placebo, P=.70) between study groups. Similarly, no significant differences in bleeding patterns existed between groups during the final 28 days.

Conclusion: Doxycycline, administered once bleeding has started, does not decrease unscheduled bleeding or shorten episodes of unscheduled bleeding in continuous oral contraceptive pill users.

Level of evidence: I.

Trial registration: ClinicalTrials.gov NCT00480532.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003;101:653–61.
    1. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89–96.
    1. Salamonsen LA, Woolley DE. Matrix metalloproteinases in normal menstruation. Hum Reprod 1996;11(suppl 2):124–33.
    1. Galant C, Berliere M, Dubois D, Verougstraete JC, Charles A, Lemoine P, et al. Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding. Am J Pathol 2004;165:83–94.
    1. Chegini N, Rhoton-Vlasak A, Williams RS. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Fertil Steril 2003;80:564–70.

Publication types

MeSH terms

Substances

LinkOut - more resources